{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:33:48Z","timestamp":1789850028953,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,19]],"date-time":"2027-06-19T00:00:00Z","timestamp":1813363200000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.ajkd.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:07:39Z","timestamp":1776701259000},"page":"99-109.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cystatin C and Creatinine\u2013Based Estimated GFR and Disease Activity Biomarkers in Rheumatoid Arthritis"],"prefix":"10.1053","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-1374","authenticated-orcid":false,"given":"Sho","family":"Fukui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Santacroce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine P.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2026.01.014_bib1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s40744-021-00346-4","article-title":"Prevalence of renal impairment in a US commercially insured rheumatoid arthritis population: a retrospective analysis","volume":"8","author":"Giles","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1053\/j.ajkd.2026.01.014_bib2","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/gfw315","article-title":"Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients","volume":"32","author":"Tokoroyama","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2026.01.014_bib3","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1681\/ASN.2009121210","article-title":"Rate of kidney function decline associates with mortality","volume":"21","author":"Al-Aly","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2026.01.014_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard-2024-226156","article-title":"Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study","volume":"84","author":"Fukui","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rdc.2018.06.008","article-title":"Renal manifestations of rheumatoid arthritis","volume":"44","author":"Kapoor","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1053\/j.ajkd.2026.01.014_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5114\/reum\/177005","article-title":"Rheumatoid arthritis\u2013medication dosage in chronic kidney disease","volume":"61","author":"Tyczy\u0144ska","year":"2023","journal-title":"Reumatologia"},{"issue":"11","key":"10.1053\/j.ajkd.2026.01.014_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45132","article-title":"Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease","volume":"6","author":"Muanda","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1053\/j.ajkd.2026.01.014_bib8","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.34067\/KID.0003202022","article-title":"Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR","volume":"3","author":"Chen","year":"2022","journal-title":"Kidney360"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41584-023-00921-9","article-title":"Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis","volume":"19","author":"Bennett","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.22540\/JFSF-08-044","article-title":"Sarcopenia in rheumatoid arthritis: a narrative review","volume":"8","author":"Moschou","year":"2023","journal-title":"J Frailty Sarcopenia Falls"},{"key":"10.1053\/j.ajkd.2026.01.014_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cca.2018.10.022","article-title":"Utility of estimated glomerular filtration rate using cystatin C and its interpretation in patients with rheumatoid arthritis under glucocorticoid therapy","volume":"487","author":"Nozawa","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.ajkd.2026.01.014_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.688246","article-title":"Kidney function in patients with neuromuscular disease: creatinine versus cystatin C","volume":"12","author":"Screever","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/ki.2010.431","article-title":"Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate","volume":"79","author":"Tangri","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib14","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2026.01.014_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2026.01.014_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2215\/CJN.12791019","article-title":"Kidney disease, race, and GFR estimation","volume":"15","author":"Levey","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: core curriculum 2021","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.01.014_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/acr2.11256","article-title":"Testing the effects of disease-modifying antirheumatic drugs on vascular inflammation in rheumatoid arthritis: rationale and design of the TARGET Trial","volume":"3","author":"Giles","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.01.014_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-024-03352-3","article-title":"Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial","volume":"26","author":"Liao","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032095","article-title":"Biomarkers of cardiovascular risk in patients with rheumatoid arthritis: results from the TARGET trial","volume":"13","author":"Solomon","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1053\/j.ajkd.2026.01.014_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/03009742.2025.2455878","article-title":"No association between vascular inflammation and estimated glomerular filtration rate in patients with rheumatoid arthritis: secondary analysis of the TARGET trial","volume":"54","author":"Fukui","year":"2025","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.01.014_bib23","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/acr.21767","article-title":"Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1053\/j.ajkd.2026.01.014_bib24","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/keae242","article-title":"Association of the multi-biomarker disease activity score with arterial 18-fluorodeoxyglucose uptake in rheumatoid arthritis","volume":"64","author":"Giles","year":"2024","journal-title":"Rheumatology"},{"issue":"6","key":"10.1053\/j.ajkd.2026.01.014_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2026.01.014_bib27","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1213\/ANE.0000000000005773","article-title":"Statistics from A (agreement) to Z (z score): a guide to interpreting common measures of association, agreement, diagnostic accuracy, effect size, heterogeneity, and reliability in medical research","volume":"133","author":"Schober","year":"2021","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1053\/j.ajkd.2026.01.014_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding Bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem Med (Zagreb)"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3899\/jrheum.2023-0218","article-title":"Cystatin C as a predictor of renal function and methotrexate-associated toxicities in patients with rheumatoid arthritis","volume":"51","author":"Kwon","year":"2023","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib31","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1038\/s41598-021-89303-3","article-title":"Factors contributing to discrepant estimated glomerular filtration values measured by creatinine and cystatin C in patients with rheumatoid arthritis","volume":"11","author":"Nakashima","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/03009740903042402","article-title":"Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis","volume":"39","author":"Sato","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1053\/j.ajkd.2026.01.014_bib33","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3899\/jrheum.110168","article-title":"Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis","volume":"38","author":"Lertnawapan","year":"2011","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/03009742.2011.571219","article-title":"Cystatin C concentration is correlated with disease activity in rheumatoid arthritis patients","volume":"40","author":"Targo\u0144ska-Stepniak","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.ajkd.2023.04.002","article-title":"Discordances between creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes in routine clinical practice","volume":"82","author":"Carrero","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2026.01.014_bib36","article-title":"Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy","volume":"3","author":"Kleeman","year":"2023","journal-title":"Cell Genom"},{"key":"10.1053\/j.ajkd.2026.01.014_bib37","article-title":"Hydroxychloroquine inhibits macrophage activation and attenuates renal fibrosis after ischemia-reperfusion injury","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2567.2001.01272.x","article-title":"Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression","volume":"103","author":"Hask\u00f3","year":"2001","journal-title":"Immunology"},{"issue":"9","key":"10.1053\/j.ajkd.2026.01.014_bib39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00296-010-1572-5","article-title":"Serum cystatin C level in patients with rheumatoid arthritis after single infusion of infliximab","volume":"31","author":"Kopec-Medrek","year":"2011","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib40","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2215\/CJN.11781017","article-title":"Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis","volume":"13","author":"Wu","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/intimm\/dxs047","article-title":"Targeting TNF receptors in rheumatoid arthritis","volume":"24","author":"Bl\u00fcml","year":"2012","journal-title":"Int Immunol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.01.014_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.ki.5002042","article-title":"Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study","volume":"71","author":"Keller","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2026.01.014_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-9-9","article-title":"Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"9","author":"Keller","year":"2008","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib44","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1038\/s41598-024-57265-x","article-title":"Circulating TNF receptor levels are associated with estimated glomerular filtration rate even in healthy individuals with normal kidney function","volume":"14","author":"Gohda","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2026.01.014_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ekir.2023.10.006","article-title":"Updates on new therapies for patients with CKD","volume":"9","author":"Tarun","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.ajkd.2026.01.014_bib46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.kint.2017.11.025","article-title":"Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease","volume":"93","author":"Sumida","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2026.01.014_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2026.01.014_bib48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/1744666X.2022.2045952","article-title":"Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives","volume":"18","author":"Kreiner","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"10.1053\/j.ajkd.2026.01.014_bib49","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2337\/dc22-0866","article-title":"Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS","volume":"45","author":"Koshino","year":"2022","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1053\/j.ajkd.2026.01.014_bib50","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:16:58Z","timestamp":1785889018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626008486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0272638626008486"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.01.014","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystatin C and Creatinine\u2013Based Estimated GFR and Disease Activity Biomarkers in Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}